Metformin as an adjuvant drug against pediatric sarcomas: Hypoxia limits therapeutic effects of the drug

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Garofalo, Cecilia ^a   Capristo, Mariantonietta ^a   Manara, Maria Cristina ^a   Mancarella, Caterina ^a   Landuzzi, Lorena ^a   Belfiore, Antonino ^b   Lollini, Pier Luigi ^c   Picci, Piero ^a   Scotlandi, Katia ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; VINCRISTINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERACTION; DRUG RESPONSE; EWING SARCOMA; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; REGULATORY MECHANISM; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL PROLIFERATION; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOENZYME TECHNIQUES; METFORMIN; MICE; MICE, NUDE; OSTEOSARCOMA; PEDIATRICS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; RNA, MESSENGER; SARCOMA, EWING; TUMOR CELLS, CULTURED; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896714232     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083832     Document Type: Article

References (65)

1. Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28: 20-47. (Pubitemid 46220849)
2. Forte V, Pandey A, Abdelmessih R, Forte G, Whaley-Connell A, et al. (2012) Obesity, Diabetes, the Cardiorenal Syndrome, and Risk for Cancer. Cardiorenal Med 2: 143-162.
3. Inoue M, Tsugane S (2012) Insulin resistance and cancer: epidemiological evidence. Endocr Relat Cancer 19: F1-8.
4. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30: 586-623.
5. Garofalo C, Mancarella C, Grilli A, Manara MC, Astolfi A, et al. (2012) Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma. Mol Endocrinol 26: 1603-1616.
6. Avnet S, Sciacca L, SalernoM, Gancitano G, Cassarino MF, et al. (2009) Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 69: 2443-2452.
7. Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R, et al. (2002) In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 21: 8240-8250. (Pubitemid 35477864)
8. Benini S, Baldini N, Manara MC, Chano T, Serra M, et al. (1999) Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer 80: 581-588. (Pubitemid 29047524)
9. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, et al. (2011) Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 30: 2730-2740.
10. Pollak MN (2012) Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2: 778-790.
11. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, et al. (2011) Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 71: 4366-4372.
12. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ (2012) Metformin in cancer: translational challenges. J Mol Endocrinol 48: R31-43.
13. Pierotti MA, Berrino F, Gariboldi M, Melani C, Mogavero A, et al. (2013) Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene 32: 1475-1487.
14. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR (2010) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33: 1304-1308.
15. Wright JL, Stanford JL (2009) Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 20: 1617-1622.
16. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766-1777.
17. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137: 482-488.
18. Chen G, Xu S, Renko K, Derwahl M (2012) Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab 97: E510-520.
19. Iliopoulos D, Hirsch HA, Struhl K (2011) Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 71: 3196-3201.
20. Hardie DG (2011) AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 25: 1895-1908.
21. Goodwin PJ, Ligibel JA, Stambolic V (2009) Metformin in breast cancer: time for action. J Clin Oncol 27: 3271-3273.
22. Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW (1993) Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res 53: 5108-5112. (Pubitemid 23333374)
23. Bagnara GP, Serra M, Giovannini M, Badiali M, Stella M, et al. (1990) Establishment and characterization of a primitive neuroectodermal tumor of bone continuous cell line (LAP-35). Int J Cell Cloning 8: 409-424. (Pubitemid 20359751)
24. Lollini PL, De Giovanni C, Landuzzi L, Nicoletti G, Scotlandi K, et al. (1991) Reduced metastatic ability of in vitro differentiated human rhabdomyosarcoma cells. Invasion Metastasis 11: 116-124.
25. De Giovanni C, Nanni P, Nicoletti G, Ceccarelli C, Scotlandi K, et al. (1989) Metastatic ability and differentiative properties of a new cell line of human embryonal rhabdomyosarcoma (CCA). Anticancer Res 9: 1943-1949.
26. Scotlandi K, Perdichizzi S, Manara MC, Serra M, Benini S, et al. (2002) Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res 8: 3893-3903. (Pubitemid 35428818)
27. Scotlandi K, Manara MC, Serra M, Benini S, Maurici D, et al. (1999) The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene 18: 739-746. (Pubitemid 29080331)
28. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, et al. (2005) Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65: 3868-3876. (Pubitemid 40616368)
29. Scotlandi K, Baldini N, Cerisano V, Manara MC, Benini S, et al. (2000) CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 60: 5134-5142.
30. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, et al. (1999) Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 5: 1935-1944. (Pubitemid 29334478)
31. Chou TC, Motzer RJ, Tong Y, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524. (Pubitemid 24330215)
32. Vazquez-Martin A, Oliveras-Ferraros C, del Barco S, Martin-Castillo B, Menendez JA (2009) mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clin Transl Oncol 11: 455-459.
33. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, et al. (2010) NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 16: 530-540.
34. Oliveras-Ferraros C, Vazquez-Martin A, Menendez JA (2009) Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. Cell Cycle 8: 1633-1636.
35. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, et al. (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752. (Pubitemid 47105521)
36. (2012) Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 Suppl 7: vii100-109.
37. Malempati S, Hawkins DS (2012) Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer 59: 5-10.
38. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, et al. (2004) Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23: 3328-3337. (Pubitemid 38669822)
39. Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, et al. (2013) Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma. Cancer 119: 1013-1022.
40. Knowles HJ, Schaefer KL, Dirksen U, Athanasou NA (2010) Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor. BMC Cancer 10: 372.
41. Aryee DN, Niedan S, Kauer M, Schwentner R, Bennani-Baiti IM, et al. (2010) Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Cancer Res 70: 4015-4023.
42. Mimeault M, Batra SK (2013) Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med 17: 30-54.
43. Kilic M, Kasperczyk H, Fulda S, Debatin KM (2007) Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 26: 2027-2038. (Pubitemid 46514744)
44. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12: 159-169.
45. Rocha GZ, Dias MM, Ropelle ER, Osorio-Costa F, Rossato FA, et al. (2011) Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res 17: 3993-4005.
46. Scotlandi K, Picci P (2008) Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol 20: 419-427.
47. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, et al. (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11: 129-135.
48. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, et al. (2011) R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 29: 4541-4547.
49. Algire C, Amrein L, Bazile M, David S, Zakikhani M, et al. (2011) Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 30: 1174-1182.
50. Toguchida J, Nakayama T (2009) Molecular genetics of sarcomas: applications to diagnoses and therapy. Cancer Sci 100: 1573-1580.
51. Zakikhani M, Blouin MJ, Piura E, Pollak MN (2010) Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123: 271-279.
52. Rozengurt E, Sinnett-Smith J, Kisfalvi K (2010) Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 16: 2505-2511.
53. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, et al. (2009) The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 69: 7662-7671.
54. Potratz JC, Saunders DN, Wai DH, Ng TL, McKinney SE, et al. (2010) Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res 70: 8770-8781.
55. Naing A, LoRusso P, Fu S, Hong DS, Anderson P, et al. (2012) Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 18: 2625-2631.
56. Subbiah V, Naing A, Brown RE, Chen H, Doyle L, et al. (2011) Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One 6: e18424.
57. Asensio-Lopez MC, Lax A, Pascual-Figal DA, Valdes M, Sanchez-Mas J (2011) Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system. Free Radic Biol Med 51: 1861-1871.
58. Kim HG, Hien TT, Han EH, Hwang YP, Choi JH, et al. (2011) Metformin inhibits P-glycoprotein expression via the NF-kappaB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol 162: 1096-1108.
59. Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, et al. (2003) Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 21: 536-542. (Pubitemid 46606485)
60. Stambolic V, Woodgett JR, Fantus IG, Pritchard KI, Goodwin PJ (2009) Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? Breast Cancer Res Treat 114: 387-389.
61. Jordan BF, Sonveaux P (2012) Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy. Front Pharmacol 3: 94.
62. Ladanyi M (2002) EWS-FLI1 and Ewing's sarcoma: recent molecular data and new insights. Cancer Biol Ther 1: 330-336.
63. Magwere T, Burchill SA (2011) Heterogeneous role of the glutathione antioxidant system in modulating the response of ESFT to fenretinide in normoxia and hypoxia. PLoS One 6: e28558.
64. Avnet S, Di Pompo G, Lemma S, Salerno M, Perut F, et al. (2013) V-ATPase is a candidate therapeutic target for Ewing sarcoma. Biochim Biophys Acta 1832: 1105-1116.
65. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, et al. (2007) HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129: 111-122. (Pubitemid 46507584)